Group 1 - The company, Dezhan Health, stated on August 11 that it currently does not produce or sell mosquito repellent water or sprays [2]

Core Viewpoint - Dezheng Health stated that the drugs displayed on its official website are mature products that have already obtained production approvals, and there are currently no new approvals expected for 2025. The company will continue to actively promote new drug research and development to provide more quality treatment options for patients [2] Group 1 - The company confirmed that all drugs showcased on its website are mature products with prior production approvals [2] - There are no new production approvals anticipated for the year 2025 [2] - The company is committed to advancing new drug research and development efforts [2]

Core Viewpoint - The company emphasizes the importance of market value management and is actively implementing measures to enhance its internal value and shareholder returns [1] Group 1: Market Value Management - The company has established a standardized management system through the formulation of the "Market Value Management System" [1] - It aims to effectively and compliantly utilize market value management tools while enhancing communication with various market participants to convey the company's value [1] Group 2: Operational Focus - The company is committed to improving operational performance to enhance quality and internal value [1] - The strategy for market value management is based on the scientific coordination and steady advancement of operational improvements to boost shareholder return capabilities [1]

德展健康（000813.SZ）8月11日在投资者互动平台表示，WYY是公司自主研发的一类创新药项目，是 主要用于治疗脑卒中的神经保护剂。目前公司正在进行WYY注射剂型的IND申报准备，计划本年度内 提交IND申请，同时公司正积极推进WYY舌下片剂型的研究。后续公司将根据相关事项进展情况，依 据法规要求及时履行披露义务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：WYY是公司自主研发的一类创新药项目？请问WYY一 类创新药进展情况如何？ ...

每经AI快讯，有投资者在投资者互动平台提问：创新药大麻二酚（CBD）相关项目进展如何？ 德展健康（000813.SZ）8月11日在投资者互动平台表示，公司子公司德义制药在研小分子大麻素创新药 目前尚处于临床前研究阶段。公司正与杨宝峰院士一道，依托院士专家工作站，积极推进大麻素创新药 领域药品研发工作，后续研发进展公司会依据法规要求及时予以披露。 （文章来源：每日经济新闻） ...

Group 1 - The company has added 14 new drugs for domestic production on its official website, which are mature products that have already obtained production licenses [2] - The company has not received any new production licenses as of 2025 and will continue to focus on new drug research and development [2] - The company aims to provide more high-quality treatment options for patients [2]

Core Viewpoint - The recombinant protein sector experienced a decline of 1.29% as of the market close on August 7, with several companies within the sector showing significant drops in stock prices [1][2]. Market Performance - The top-performing concept sectors included rare earth permanent magnets (+3.24%), brain-computer interfaces (+2.69%), and hyperbaric oxygen chambers (+2.56%), while the recombinant protein sector was among the worst performers [2]. - Within the recombinant protein sector, companies such as Zhifei Biological, ShenZhou Cell, and Dezheng Health saw the largest outflows of main funds, with net outflows of 1.22 billion, 1.12 billion, and 1.10 billion respectively [2][3]. Fund Flow Analysis - The recombinant protein sector experienced a net outflow of 867 million in main funds today, with 37 stocks seeing outflows, and 10 stocks having outflows exceeding 50 million [2]. - The stocks with the highest net inflows included Borui Pharmaceutical, Rejing Biological, and Marumi Biological, with inflows of 2.33 billion, 16.48 million, and 16.39 million respectively [2][4]. Stock Performance - Notable declines in stock prices within the recombinant protein sector included: - Zhifei Biological: -1.06% - ShenZhou Cell: -4.57% - Dezheng Health: -1.65% - Beida Pharmaceutical: -2.53% - Maiwei Biological: -5.31% [2][3]. - Conversely, stocks that increased in value included: - *ST Suwu: +4.63% - Marumi Biological: +3.55% - Fulejia: +1.17% [1][4].

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

创新药概念股集体走低，奥翔药业（603229）触及跌停，科兴制药跌超10%，塞力医疗（603716）、德 展健康（000813）、海创药业跌幅居前。 ...